Stanley Plotkin

Last updated
Stanley Alan Plotkin
Photo Plotkin1.jpg
Born (1932-05-12) 12 May 1932 (age 91)
Alma mater SUNY Downstate Medical Center
Known for Vaccinology, immunology
SpouseSusan Plotkin
Children2

Stanley Alan Plotkin (born May 12, 1932 [1] ) is an American physician who works as a consultant to vaccine manufacturers, such as Sanofi Pasteur, as well as biotechnology firms, non-profits and governments. In the 1960s, he played a pivotal role in discovery of a vaccine against rubella virus while working at Wistar Institute in Philadelphia. Plotkin was a member of Wistar’s active research faculty from 1960 to 1991. Today, in addition to his emeritus appointment at Wistar, he is emeritus professor of Pediatrics at the University of Pennsylvania. His book, Vaccines, [2] [3] is the standard reference on the subject. [4] [5] He is an editor with Clinical and Vaccine Immunology , which is published by the American Society for Microbiology in Washington, D.C.

Contents

Early life and education

Plotkin was born and raised in New York City, the son of Jewish parents, Lee and Joseph Plotkin, who emigrated from England. He attended The Bronx High School of Science in New York City. While attending Bronx Science, at the age of 15, he read a pair of books that greatly influenced his future education and career choices: Arrowsmith by Sinclair Lewis and Microbe Hunters by Paul de Kruif. Deciding to dedicate his life to being a physician and research scientist, Plotkin graduated from Bronx Science in 1948. He then earned his bachelor's degree from New York University in 1952 and went on to earn his MD at SUNY Downstate Medical Center in 1956. [5] [6] Plotkin received his GME from the School of Medicine, University of Pennsylvania in 1963. [7] [8]

Career

The Wistar Institute of Anatomy and Biology

During his time at Wistar, Plotkin worked on several vaccines; chief among them are vaccines for rubella, rabies, rotavirus, and cytomegalovirus (CMV). He developed a vaccine for rubella, based upon the RA 27/3 strain of the virus (also developed by Plotkin using WI-38, a fetal-derived human cell line), which was released to the public in 1969. [9] The enabling technology was the WI-38 cell strain gifted to Plotkin by Leonard Hayflick also of the Wistar. WI-38 provide the key elements for the successful Rubella vaccine. The virus became attenuated when grown on WI-38; it was free of unwanted viruses and the vaccine proved to have minor side effects when compared with the HPV vaccine developed at the NIH. This WI-38 grown vaccine led to the eradication of the disease in the United States, according to the Centers for Disease Control and Prevention, in 2005. [10] Plotkin, working with Tadeusz Wiktor and Hilary Koprowski, produced a human vaccine for rabies during the 1960s and 1970s also on the WI-38 cell strain gifted to them by Leonard Hayflick. WI-38 provided to the rabies vaccine the same properties that it gave to the rubella vaccine. This rabies vaccine can be used as a preventive measure for people who have an increased risk of contracting rabies, as well as a treatment for those who have been exposed recently to the disease, preventing infection in nearly 100 percent of cases. [10] Another vaccine that Plotkin co-developed, working with H. Fred Clark and Paul Offit, is for rotavirus. In 2006, the team's vaccine became part of the U.S. recommended vaccine schedule for babies. [10] In the 1970s, Plotkin led the development of an experimental vaccine against CMV. This vaccine, developed using attenuated CMV, has yet to make it into commercial production. [10]

Dr. Plotkin has been a tireless advocate for the protection of humans, and children in particular, from preventable infectious diseases. His lifetime of work on vaccines has led to profound reductions in both morbidity and mortality not only in the United States, but throughout the world. His unbending adherence to the principle of being guided by outstanding science has led him to be admired by his peers. He demonstrates the combination of scholar, scientist and public servant exemplified by Dr. Maxwell Finland.

Vijay B. Samant, President and CEO of Vical, Inc. [5]

Other positions held

Awards

Personal life

Plotkin and his wife, Susan, have two children, Michael and Alec. In 1957, Plotkin wanted to join the US Air Force so that he could learn to fly, but instead he went to work for the Epidemic Intelligence Service. He eventually realized his dream of learning to fly at the age of 74. [6]

Selected publications

Related Research Articles

<span class="mw-page-title-main">Vaccine</span> Pathogen-derived preparation that provides acquired immunity to an infectious disease

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious or malignant disease. The safety and effectiveness of vaccines has been widely studied and verified. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and recognize further and destroy any of the microorganisms associated with that agent that it may encounter in the future.

<span class="mw-page-title-main">MMR vaccine</span> Any of several combined vaccines against measles, mumps, and rubella

The MMR vaccine is a vaccine against measles, mumps, and rubella, abbreviated as MMR. The first dose is generally given to children around 9 months to 15 months of age, with a second dose at 15 months to 6 years of age, with at least four weeks between the doses. After two doses, 97% of people are protected against measles, 88% against mumps, and at least 97% against rubella. The vaccine is also recommended for those who do not have evidence of immunity, those with well-controlled HIV/AIDS, and within 72 hours of exposure to measles among those who are incompletely immunized. It is given by injection.

<span class="mw-page-title-main">Rubella</span> Human viral disease

Rubella, also known as German measles or three-day measles, is an infection caused by the rubella virus. This disease is often mild, with half of people not realizing that they are infected. A rash may start around two weeks after exposure and last for three days. It usually starts on the face and spreads to the rest of the body. The rash is sometimes itchy and is not as bright as that of measles. Swollen lymph nodes are common and may last a few weeks. A fever, sore throat, and fatigue may also occur. Joint pain is common in adults. Complications may include bleeding problems, testicular swelling, encephalitis, and inflammation of nerves. Infection during early pregnancy may result in a miscarriage or a child born with congenital rubella syndrome (CRS). Symptoms of CRS manifest as problems with the eyes such as cataracts, deafness, as well as affecting the heart and brain. Problems are rare after the 20th week of pregnancy.

This is a timeline of the development of prophylactic human vaccines. Early vaccines may be listed by the first year of development or testing, but later entries usually show the year the vaccine finished trials and became available on the market. Although vaccines exist for the diseases listed below, only smallpox has been eliminated worldwide. The other vaccine-preventable illnesses continue to cause millions of deaths each year. Currently, polio and measles are the targets of active worldwide eradication campaigns.

Leonard Hayflick is a Professor of Anatomy at the UCSF School of Medicine, and was Professor of Medical Microbiology at Stanford University School of Medicine. He is a past president of the Gerontological Society of America and was a founding member of the council of the National Institute on Aging (NIA). The recipient of a number of research prizes and awards, including the 1991 Sandoz Prize for Gerontological Research, he has studied the aging process for more than fifty years. He is known for discovering that normal human cells divide for a limited number of times in vitro. This is known as the Hayflick limit. His discoveries overturned a 60-year old dogma that all cultured cells are immortal. Hayflick demonstrated that normal cells have a memory and can remember at what doubling level they have reached. He demonstrated that his normal human cell strains were free from contaminating viruses. His cell strain WI-38 soon replaced primary monkey kidney cells and became the substrate for the production of most of the world's human virus vaccines. Hayflick discovered that the etiological agent of primary atypical pneumonia was not a virus as previously believed. He was the first to cultivate the causative organism called a mycoplasma, the smallest free-living organism, which Hayflick isolated on a unique culture medium that bears his name. He named the organism Mycoplasma pneumoniae.

<span class="mw-page-title-main">Hilary Koprowski</span> Polish-Jewish-American physician, virologist, immunologist and medical researcher

Hilary Koprowski was a Polish virologist and immunologist active in the United States who demonstrated the world's first effective live polio vaccine. He authored or co-authored over 875 scientific papers and co-edited several scientific journals.

<span class="mw-page-title-main">Maurice Hilleman</span> American vaccinologist (1919–2005)

Maurice Ralph Hilleman was a leading American microbiologist who specialized in vaccinology and developed over 40 vaccines, an unparalleled record of productivity. According to one estimate, his vaccines save nearly eight million lives each year. He has been described as one of the most influential vaccinologists ever. He has been called the "father of modern vaccines". Robert Gallo called Hilleman "the most successful vaccinologist in history". He has been noted by some researchers as having saved more lives than any other scientist in the 20th century.

<span class="mw-page-title-main">Wistar Institute</span> American biomedical research institute

The Wistar Institute is an independent, nonprofit research institution in biomedical science with special focuses in oncology, immunology, infectious disease and vaccine research. Located on Spruce Street in Philadelphia’s University City neighborhood, Wistar was founded in 1892 as a nonprofit institution to focus on biomedical research and training.

<i>Human betaherpesvirus 5</i> Species of virus

Human betaherpesvirus 5, also called human cytomegalovirus (HCMV,HHV-5), is a species of virus in the genus Cytomegalovirus, which in turn is a member of the viral family known as Herpesviridae or herpesviruses. It is also commonly called CMV. Within Herpesviridae, HCMV belongs to the Betaherpesvirinae subfamily, which also includes cytomegaloviruses from other mammals. CMV is a double-stranded DNA virus.

An attenuated vaccine is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable. Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent. These vaccines contrast to those produced by "killing" the pathogen.

<span class="mw-page-title-main">Rabies vaccine</span> Vaccines to prevent rabies in humans and animals

The rabies vaccine is a vaccine used to prevent rabies. There are several rabies vaccines available that are both safe and effective. Vaccinations must be administered prior to rabies virus exposure or within the latent period after exposure to prevent the disease. Transmission of rabies virus to humans typically occurs through a bite or scratch from an infectious animal, but exposure can occur through indirect contact with the saliva from an infectious individual.

Clarence James Peters, Jr is a physician, field virologist and former U.S. Army colonel. He is noted for his efforts in trying to stem epidemics of exotic infectious diseases such as the Ebola virus, Hanta virus and Rift Valley fever (RVF). He is an eminent authority on the virology, pathogenesis and epidemiology of hemorrhagic fever viruses.

<span class="mw-page-title-main">Rubella vaccine</span> Vaccine used to prevent rubella

Rubella vaccine is a vaccine used to prevent rubella. Effectiveness begins about two weeks after a single dose and around 95% of people become immune. Countries with high rates of immunization no longer see cases of rubella or congenital rubella syndrome. When there is a low level of childhood immunization in a population it is possible for rates of congenital rubella to increase as more women make it to child-bearing age without either vaccination or exposure to the disease. Therefore, it is important for more than 80% of people to be vaccinated. By introducing rubella containing vaccines, rubella has been eradicated in 81 nations, as of mid-2020.

<span class="mw-page-title-main">Inactivated vaccine</span> Vaccine using a killed version of a disease pathogen

An inactivated vaccine is a vaccine consisting of virus particles, bacteria, or other pathogens that have been grown in culture and then killed to destroy disease-producing capacity. In contrast, live vaccines use pathogens that are still alive. Pathogens for inactivated vaccines are grown under controlled conditions and are killed as a means to reduce infectivity and thus prevent infection from the vaccine.

Ann M. Arvin is an American pediatrician and microbiologist. She is the Lucile Salter Packard Professor of Pediatrics and Professor of Microbiology & Immunology Emerita at Stanford University. Arvin is a specialist of the Varicella zoster virus (VZV) and a prominent national figure in health. Arvin is currently the chief of the infectious diseases division of pediatrics at the Lucile Packard Children's Hospital, as well as the former Stanford's Vice Provost and Dean of Research.

<span class="mw-page-title-main">WI-38</span> Human cell line composed of fibroblasts

WI-38 is a diploid human cell line composed of fibroblasts derived from lung tissue of a 3-month-gestation female fetus. The fetus came from the elective abortion of a Swedish woman in 1963. The cell line was isolated by Leonard Hayflick the same year, and has been used extensively in scientific research, with applications ranging from developing important theories in molecular biology and aging to the production of most human virus vaccines. The uses of this cell line in human virus vaccine production is estimated to have saved the lives of millions of people.

Werner Henle and Gertrude Henle were a husband and wife team of German-American virologists. The National Library of Medicine called them "a prodigious force in virology, immunology and viral oncology during the second half of the 20th century".

Michael Katze was an American microbiologist. For over 35 years, he has researched host-virus interactions, incorporating systems biology approaches into infectious disease research. He was an international leader in the application of genome sequencing, animal models, and systems biology approaches to virology and immunology. Katze was formerly Professor of Microbiology at the University of Washington (UW), and Associate Director for Molecular Sciences and a Core Staff Scientist at the Washington National Primate Research Center. In August 2017, Katze was fired from the University of Washington for sexually harassing his employees and misusing research funds.

<span class="mw-page-title-main">H. Fred Clark</span> American veterinarian

H. Fred Clark was an American veterinarian, medical scientist, and social activist. He served as a research professor of pediatrics at the University of Pennsylvania's Perelman School of Medicine and at the Children's Hospital of Philadelphia, as well as holding the position of adjunct professor at the Wistar Institute. He is recognized for his work with Paul Offit and Stanley Plotkin developing the rotavirus vaccine RotaTeq. For this work, Clark, Offit, and Plotkin received the Children's Hospital of Philadelphia's Gold Medal in 2006. He received a degree in veterinary medicine from Cornell University and a Ph.D. in microbiology and immunology from the University of Buffalo.

References

  1. "Brasil, Cartões de Imigração, 1961: Stanley Alan Plotkin". FamilySearch .
  2. Plotkin, Stanley A; Orenstein, Walter A (2004). Vaccines. Philadelphia, Pa.: Saunders. ISBN   0721696880. OCLC   51811284.
  3. Orenstein, Stanley (1999). "Smallpox and Vaccinia". In Stanley A. Plotkin, Walter A. (ed.). Vaccines (3rd ed.). Philadelphia: W.B. Saunders Co. ISBN   0721674437.
  4. 1 2 3 "Dr. Stanley Plotkin talks CMV vaccine research". National CMV Foundation. Retrieved 9 August 2017.
  5. 1 2 3 4 5 6 7 Christian H. Ross (13 Apr 2017). "Stanley Alan Plotkin (1932- )". The Embryo Project Encyclopedia. Archived from the original on 14 August 2017. Retrieved 14 Aug 2017.
  6. 1 2 3 4 "Stanley A. Plotkin, MD" (PDF). National Foundation for Infectious Diseases. Retrieved 9 August 2017.
  7. "PENN MED SPRING 2002" (PDF). University of Pennsylvania Medical Center. p. 29. Retrieved 6 October 2017.
  8. 1 2 "Distingished [sic] Graduate Award". Perelman School of Medicine at the University of Pennsylvania . Retrieved 6 October 2017.
  9. Offit, Paul (2007), Vaccinated: One Man's Quest to Defeat the World's Deadliest Diseases, New York, New York: HarperCollins Inc, pp.  78–89, ISBN   978-0-06-122795-0
  10. 1 2 3 4 "History". Wistar. Retrieved 4 August 2017.
  11. Nemeh, Katherine H., ed. (2014). American Men & Women of Science: A Biographical Directory of Today's Leaders in Physical, Biological and Related Sciences (32nd ed.). p. 1434. ISBN   978-1414497181.
  12. 1 2 3 4 "Plotkin, MD". Agence de Médecine Préventive. Archived from the original on 14 August 2017. Retrieved 14 Aug 2017.
  13. Florence Pat Haseltine (14 January 2014). "Prominent Virologist Stanley Plotkin Joins GVN as Senior Advisor". Global Virus Network. Archived from the original on 14 August 2017. Retrieved 14 Aug 2017.
  14. "Scientific Advisory Board". Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery. Archived from the original on 2015-08-03. Retrieved 14 Aug 2017.
  15. "Stanley A. Plotkin". Johns Hopkins Bloomberg School of Public Health. Archived from the original on 14 August 2017. Retrieved 14 Aug 2017.
  16. "About". Mymetics. Archived from the original on 2016-11-14. Retrieved 14 Aug 2017.
  17. Clive Cookson (18 January 2017). "Davos launch for coalition to prevent epidemics of emerging viruses". Financial Times . Retrieved 6 March 2020. Billion-dollar programme aims to cut vaccine-development time from 12 years to one
  18. John Cohen (2 September 2016). "New vaccine coalition aims to ward off epidemics". Science. 353 (6303).
  19. "James D. Bruce Memorial Award for Distinguished Contributions in Preventive: Full Lists of Recipients" (PDF). Awards, Masterships & Competitions. American College of Physicians. Archived from the original (PDF) on 5 August 2017. Retrieved 5 Aug 2017.
  20. "Distinguished Physician". Pediatric Infectious Diseases Society. Archived from the original on 5 August 2017. Retrieved 5 Aug 2017.
  21. "Past Award Recipients". Pan-American Society for Clinical Virology. Archived from the original on 5 August 2017. Retrieved 5 Aug 2017.
  22. "Dr. Plotkin receives French award for role in developing vaccines". AAP News & Journals Gateway. 1 Aug 1998. Archived from the original on 14 August 2017. Retrieved 14 Aug 2017.
  23. "The Albert B. Sabin Gold Medal Award". Sabin. Archived from the original on 5 August 2017. Retrieved 5 Aug 2017.
  24. "Wistar Emeritus Professor Stanley A. Plotkin, M.D., Elected to Institute of Medicine". Wistar. Archived from the original on 13 May 2013. Retrieved 4 August 2017.
  25. "How to Nominate for ASM Awards and Prize, Past Laureates, page 24". February 1, 2023.
  26. "Maxwell Finland Award for Scientific Achievement". National Foundation for Infectious Diseases. Retrieved 9 August 2017.
  27. Ben Leach (11 November 2013). "The Wistar Gala Honors Brian H. Dovey and Stanley A. Plotkin, M.D." Wistar. Archived from the original on 4 August 2017. Retrieved 4 August 2017.
  28. "Dr. Stanley A. Plotkin to Receive the Hamdan Award for Medical Research Excellence in the Field of Vaccines". Wistar. Archived from the original on 9 October 2015. Retrieved 4 August 2017.
  29. "Dr. Charles Mérieux Award for Achievement in Vaccinology and Immunology". National Foundation for Infectious Diseases. 29 August 1999. Archived from the original on 6 June 2017. Retrieved 14 Aug 2017.